Arabinoxylan rice bran (MGN-3) enhances the effects of interventional therapies for the treatment of hepatocellular carcinoma: A three-year randomized clinical trial

Anticancer Research

Volumn 30, Issue 12, 2010, Pages 5145-5152

  Hong Bang, Mai Hong ^a   Van Riep, Tran ^a   Thinh, Nguyen Tien ^a   Huu Song, L E ^a   Dung, Trinh Tuan ^a   Van Truong, L E ^a   Van Don, L E ^a   Thai Doan, K Y ^a   Deyu, Pan ^b   Shaheen, Magda ^b   Ghoneum, Mamdooh ^b  

^a Central University Hospital 108   (Viet Nam)

^b CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

Author keywords

Angiogram; HCC; MGN 3; Recurrence

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ARABINOXYLAN; DOXORUBICIN; IODINATED POPPYSEED OIL;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; INTERVENTION STUDY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIDETECTOR COMPUTED TOMOGRAPHY; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL; RICE BRAN; SURVIVAL TIME; TRANSARTERIAL OILY CHEMOEMBOLIZATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DOUBLE-BLIND METHOD; DOXORUBICIN; ETHANOL; ETHIODIZED OIL; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; XYLANS;

EID: 78751551142     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics 2002. CA-A Cancer J Clin 55: 74-108, 2005.
2. El Serag HB and Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340: 745-750, 1999.
3. Kew M: Tumors of the Liver. In: Hepatology: A Textbook of Liver Disease, 2nd edition Vol 2. Zakim D and Boyer TD (eds.). WB Saunders Company, Philadelphia, PA, USA, pp. 1206-1240, 1990.
4. Callstrom MR and Charboneau JW: Technologies for ablation of hepatocellular carcinoma. Gastroenterology 134: 1831-1835, 2008.
5. Cheng BQ, Jia CQ, Liu CT, Fan W, Wang QL, Zhang ZL and Yi CH: Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA 299: 1669-1677, 2008.
6. Ramsey DE, Kernagis LY, Soulen MC and Geschwind JFH: Chemoembolization of hepatocellular carcinoma. J Vase Interv Radiol 13: S211-221, 2002.
7. Group d'Etude et de Traitement du Carcinome Hepatocellulaire: A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire N Engl J Med 552: 1256-1261, 1995.
8. Ghoneum M: Anti-HIV activity in vitro of MGN-3, an activated arabinoxylan from rice bran. Biochem Biophys Res Commun 243: 25-29, 1998.
9. Ghoneum M: Enhancement of human natural killer cell activity by modified arabinoxylan from rice bran (MGN-3). Int J Immunother 14: 89-99, 1998.
10. Ghoneum M and Abedi S: Enhancement of natural killer cell activity of aged mice by modified arabinoxylan rice bran (MGN3). J Pharmacy Pharmacol 56: 1581-1588, 2004.
11. Noaman E, Badr El-Din N, Bibars M, Mossallam AAA and Ghoneum M: Antioxidant potential by arabinoxylan rice bran, MGN-3, represents a mechanism for its oncostatic effect against murine solid Ehrlich carcinoma. Cancer Lett 265: 348-359, 2008.
12. Ghoneum M and Gollapudi S: Modified arabinoxylan rice bran (MGN-3) sensitizes human T-cell leukemia cells to death receptors (CD95)-induced apoptosis. Cancer Lett 201: 41-49, 2003.
13. Gollapudi S and Ghoneum M: MGN-3, modified arabinoxylan rice bran, sensitizes human breast cancer cells to chemotherapeutic agent, daunorubicin. Cancer Detect Prev 32: 1-6, 2008.
14. Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F and Kondo Y: Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma: study of 95 patients. J Gastroenterol Hepatol 5: 616-626, 1990.
15. Vilana R, Bruix J, Bru C, Ayuso C, Sole M and Rodes J: Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 16: 353-357, 1992.
16. Bruix J, Castells A, Montanya X, Calvet X, Bry C, Ayuso C, Jover L, Garcia L, Vilana R, Boix L and Rodes J: Phase II study of transarterial embolization in European patients with hepatocellular carcinoma: need for controlled trials. Hepatology 20: 643-650, 1994.
17. Trevisani F, De Notariis S, Rossi C and Bernardi M: Randomized control trials on chemoembolization for hepatocellular carcinoma: is there room for new studies? J Clin Gastroenterol 32: 383389, 2001.
18. Urabe T, Kaneko S, Matsushita E, Unoura M and Kobayashi K: Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 55: 39-47, 1998.
19. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S and Monden M: Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 94: 435-442, 2002.
20. Ota H, Nagano H, Sakon M, Eguchi H, Kondo M, Yamamoto T, Nakamura M, Damdinsuren B, Wada H, Marubashi S, Miyamoto A, Dono K, Umeshita K, Nakamori S, Wakasa K and Monden M: Treatment of hepatocellular carcinoma with major portal vein thrombosis by combined therapy with subcutaneous interferonalpha and intra-arterial 5-fluorouracil; role of type 1 interferon receptor expression. Br J Cancer 93: 557-564, 2005.
21. Hamabe ST, Yamasaki T, Saeki I, Harima Y, Okita K, Terai S and Sakaida I: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: Is the addition of subcutanesous interferon-a-2b beneficial? Hepatol Res 39: 223230, 2009.
22. Eun JR, Lee HJ, Moon HJ, Kim TN, Kim JW and Chang JC: Hepatic arterial infusion chemotherapy using high-dose 5fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol 44: 1477-1486, 2009.
23. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasak D, Yoshida Y, and Sakata Y: Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer Chemother Pharmacol 33: S 145-148, 1994.
24. Lissoni P, Messina G, Brivio F, Fumagalli L, Vigoré L, Rovelli F, Maruelli L, Miceli M, Marchiori P, Porro G, Held M, di Fede G and Uchiyamada T: Modulation of the anticancer immunity by natural agents: inhibition of T regulatory lymphocyte generation by arabinoxylan in patients with locally limited or metastatic solid tumors. Cancer Therapy 6: 1011-1116, 2008.
25. Badr El-Din NK, Noaman E and Ghoneum M: In vivo tumor inhibitory effects of nutritional rice bran supplement MGN3/Biobran on Ehrlich carcinoma-bearing mice. Nutrition Cancer 60: 235-244, 2008.
26. Takahara K and Sano K: The life prolongation and QOL improvement effect of rice bran arabinoxylan derivative (MGN3, BioBran) for progressive cancer. Clin Pharmacol Therapy 14: 267-271, 2004.
27. Brookes RH, Kew MC and Rabson AR: Depressed natural cytotoxicity but normal natural killer cytotoxic factor (NKCF) production by mononuclear cells derived from patients with hepatocellular carcinoma. Cancer Immunol Immunother 25: 149152, 1987.
28. Chuang WL, Liu HW and Chang WY: Natural killer cell activity in patients with hepatocellular carcinoma relative to early development and tumor invasion. Cancer 65: 926-930, 1990.
29. Engleman EG: Dendritic cell-based cancer immunotherapy. Semin Oncol 30 (3 Suppl 8): 23-29, 2003.
30. Ghoneum M and Brown J: NK immunorestoration of cancer patients by MGN-3, a modified arabinoxylan rice bran (study of 32 patients followed for up to 4 years). In: Anti-aging Medical Therapeutics, Vol. III. Klatz R and Goldman R (eds.). Health Quest Publications, Marina del Rey, CA, USA, pp. 217-226, 1999.
31. Ghoneum M and Jewett A: Production of tumor necrosis factoralpha and interferon-gamma from human peripheral blood lymphocytes by MGN-3, a modified arabinoxylan from rice bran, and its synergy with interleukin-2 in vitro. Cancer Detect Prev 24: 314-324, 2000.
32. Cholujova D, Jakubikova J and Sedlak J: BioBran-augmented maturation of human monocyte-derived dendritic cells. Neoplasma 56: 89-95, 2009.
33. Endo Y and Kanbayashi H: Modified rice bran beneficial for weight loss of mice as a major and acute adverse effect of cisplatin. Pharmacol Toxicol 92: 300-303, 2003.
34. Jacoby HI, Wnorowski G, Sakata K and Maeda H: The effect of MGN-3 on cisplatin and adriamycin induced toxicity in the rat. J Nutraceut Funct Med Foods 5: 3-11, 2001.
35. Tazawa K: BioBran/MGN-3: Basic and Clinical Application to Integrative Medicine. Iyakushuppan Co. Publishers, Japan, 2003.